OH-PROCTER-&-GAMBLE
11.1.2021 11:02:32 CET | Business Wire | Press release
Procter & Gamble (P&G) Oral Care seeks to advance healthy oral care habits to transform people’s health while reducing impact on the planet through its new sustainability commitments. The platform, “Healthy Smiles. Healthy Lives. Healthy Planet.”, guides its oral care brands, including Oral-B and Crest, to help unlock the lifechanging power of healthy oral care habits for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005056/en/
The World Health Organization estimates oral diseases affect 3.58 billion people, with cavities being the most prevalent issue. Both Oral-B and Crest are working to educate and enable 2 billion people to adopt healthy oral care habits by 2030, reducing their environmental footprint and enabling responsible consumption along the way.
“We are on a mission to help more people around the world understand the connection of their oral care routine to their overall health and how small changes can make a big impact,” said Alexandra Vegas, Senior Vice President Global Oral Care, P&G. “As we encourage everyone to brush twice daily for two minutes, we’ll continue to introduce products that make people want to build those healthy habits.”
Oral-B and Crest will focus their efforts on education and advocacy; enabling access to dental products and services; and innovation that makes the adoption of healthy habits enjoyable. Oral-B’s free Disney Magic Timer app, for example, is making 90% of kids brush for longer, establishing healthy brushing habits early on in childhood.
Healthy Habits for People
To drive healthy habits for people, Oral-B and Crest will improve access to oral care solutions and education to establish better oral health habits and continue to provide safe products with transparency.
During the COVID-19 pandemic, when people couldn’t visit their dentist, the brands helped protect oral health through educational articles, videos and livestreaming sessions. In the U.S., they have donated millions in product and dental care through their partnerships with Feeding America, Dental Lifeline Network and America’s Tooth Fairy. Oral-B and Crest will continue to partner with dental professionals, retailers and consumers to make progress.
Healthy Habits for the Planet
To drive healthy habits for the planet, Oral-B and Crest will encourage and enable responsible consumption by making their packaging 100% recyclable, starting with the transition to recyclable toothpaste tubes in Europe, the U.S. and Canada by 2025.
P&G Oral Care will also reduce its environmental footprint and strive for circular solutions while working with suppliers to secure transparent and responsible sourcing. Specific goals include reducing greenhouse gas emissions in operations and improving water efficiency by 35% in P&G sites by 2030.
Today P&G Oral Care factories send zero manufacturing waste to landfill globally, and all U.S. and European sites purchase 100% renewable electricity. The company has improved energy efficiency across its global Oral Care production sites by nearly 20% since 2010.
These goals are rooted in P&G's Ambition 2030 Sustainability Program, as well as three United Nations’ Sustainable Development Goals: Good Health and Wellbeing, Responsible Consumption and Production, and Reduced Inequality.
“We take a holistic approach in the way we design our oral health innovation, considering both the health of people and our planet,” said Lisa Ernst, Senior Vice President Oral Care R&D, P&G. “For example, our Oral-B electric toothbrushes help people brush better for longer and reduce oral care issues such as gum inflammation. For people who prefer to use manual toothbrushes, Oral-B Clic features replaceable toothbrush heads that reduce plastic waste by 60%.”
Visit the Oral-B website for more details on “Healthy Smiles. Healthy Lives. Healthy Planet.”
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
